VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2020 | Pacritinib activity against myelofibrosis

John Mascarenhas, MD, of of the Icahn School of Medicine at Mount Sinai, New York, NY, discusses pacritinib, a JAK2 and FLT3 inhibitor, investigated in myelofibrosis, as well as the results of the PERSIST-2 study (NCT02055781), evaluating this agent against best available therapy in myelofibrosis patients with thrombocytopenia. Dr Mascarenhas also elaborates on the ongoing Phase III PACIFICA study (NCT03165734) evaluating pacritinib in patients with primary myelofibrosis, post polycythemia vera myelofibrosis, or post-essential thrombocytopenia myelofibrosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Disclosures

John Mascarenhas, MD, has done consultancy work with Celgene/BMS, Prelude, Galecto, Promedior, Geron, Constellation and Incyte, and has received research funding from Incyte, Kartos, Roche, Promedior, Merck, Merus, Arog, CTI Biopharma, Janssen and PharmaEssentia.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter